Active · per the CBE, 16 September 2026

THEODORUS IV

BE0707902931

Rechtspersoon Public limited company 1 establishment

Researchdreef 12, 1070 Anderlecht

Active for

7 year, 11 months

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

  • Two loss years in a row NBB

    Negative result in 2023 and 2024.

  • Busy address KBO

    60 other companies have their registered office at the same address; threshold 10.

  • Not on Peppol Peppol

    Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2024

THEODORUS IV from Anderlecht, company number BE0707902931, closed financial year 2024 with a result of € -2.4 million after tax. For that financial year THEODORUS IV recorded a gross margin of € -717,536 and equity of € 12 million. Compared with financial year 2023, the result moved from € -2.3 million to € -2.4 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 14, 2025.

What it is worth Growing

€ 12 million

▲ 34% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -2.4 million

▼ 6 % more loss than in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 323,713

▼ 77% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -8.2 million.

Debts at end 2024

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 8,016

▲ 52% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
2021202220232024Change 2023 → 2024
Gross margin € -835,470 € -858,348 € -938,471 € -717,536 ▲ € 220,935
Profit after taxes € -872,230 € -1,017,180 € -2,279,292 € -2,408,224 ▼ € 128,931
Equity € 9,012,742 € 11,283,062 € 9,003,770 € 12,026,945 ▲ 34%
Total debts € 15,988 € 34,603 € 218,990 € 61,539 ▼ 72%
Cash € 3,903,770 € 2,890,603 € 1,413,958 € 323,713 ▼ 77%
Retained profit € -2,493,508 € -3,510,688 € -5,789,980 € -8,198,204 ▼ € 2.4 million
Balance sheet total € 9,028,730 € 11,317,665 € 9,222,760 € 12,088,484 ▲ 31%

Key figures of THEODORUS IV, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to THEODORUS IV?

What happened at THEODORUS IV in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • Finadvize SRL stepped down as director. NBB
  • Finance & Invest.brussels stepped down as director. NBB
  • Université Livre de Bruxelles stepped down as director. NBB
  • Square L SA stepped down as director. NBB
  • 50° North Ventures Sa stepped down as director. NBB
  • Société Fédérale de Participations et d'Investissement SA stepped down as director. NBB
  • BNP Paribas Fortis Private Equity Management SA stepped down as director. NBB
  • Alexandre Franco stepped down as director. NBB

In short

From € 872,230 loss in 2021 to € 2.4 million loss in 2024.

Management

The stake of V.D.B. FACULTY, finance&invest.brussels comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

THEODORUS IV

The shares are held by Société Fédérale de Participations et d'Investissements (30.4%), Sambrinvest Spin-Off/Spin-Out SA (15.2%), V.D.B. FACULTY (25%) and finance&invest.brussels (6.1%). It owns 60% of GEPECERON (ouverture faillite), 31.6% of INHATARGET THERAPEUTICS, 29.7% of KAPCARE, 19.7% of NEUVASQ BIOTECHNOLOGIES and 18.9% of NEOMABS BIOTECHNOLOGIES INC itself.

See the full network in the app

Directors

According to the 2024 annual accounts

Finadvize SRL

Director · represented by Ilan Zatalovski

Also active at: KREST 3

since 2024 · until 2030

Square L SA

Director · represented by Claude Jottrand

since 2024 · until 2030

50° North Ventures Sa

Managing director · represented by André Ostachkov

Also active at: EEBIC, BE ANGELS, Brussels South Charleroi BioPark Dev, THEODORUS III, THEODIRIS, ALLERINVEST, KABANDY, SEEDER FUND +13 more

since 2024 · until 2030

since 2024 · until 2030

Alexandre Franco

Director

since 2024 · until 2030

since 2024 · until 2030

Participations

Establishments

Establishment units

Physical locations of this company

Registered office

Researchdreef 12

1070 Anderlecht

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number
0707.902.931
VAT number
BE 0707.902.931
Registered office
Researchdreef 12, 1070 Anderlecht
Names & denominations
THEODORUS IV
Enterprise type
Rechtspersoon
Legal form
Public limited company
Legal situation
Normale toestand
Start date
8 October 2018
Peppol
Not registered

Frequently asked questions

What is the address of THEODORUS IV?
The registered office of THEODORUS IV is located at Researchdreef 12, 1070 Anderlecht.
Is THEODORUS IV still active?
Yes. According to the CBE (16 September 2026) THEODORUS IV is active, legal situation “Normale toestand”, started on 8 October 2018.
Is THEODORUS IV registered on Peppol?
No, THEODORUS IV is currently not registered on the Peppol network.
What is the enterprise number of THEODORUS IV?
The enterprise number of THEODORUS IV is BE0707902931.
When was THEODORUS IV founded?
THEODORUS IV was founded on 8 October 2018.
Who owns THEODORUS IV?
The shares are held by Société Fédérale de Participations et d'Investissements (30.4%), Sambrinvest Spin-Off/Spin-Out SA (15.2%), V.D.B. FACULTY (25%) and finance&invest.brussels (6.1%). It owns 60% of GEPECERON (ouverture faillite), 31.6% of INHATARGET THERAPEUTICS, 29.7% of KAPCARE, 19.7% of NEUVASQ BIOTECHNOLOGIES and 18.9% of NEOMABS BIOTECHNOLOGIES INC itself.